|

NALIRIFOX Clinical Trials

5 actively recruiting trials across 4 locations

Also known as: A combination of liposomal irinotecan,5 fluorouracil /leucovorin and oxaliplatin.

Other1 trial

NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial
Phase 2

San Diego, California1 trial

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

University of California San Diego Moores Cancer Center

Phase 1

Aurora, Colorado1 trial

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

University of Colorado Cancer Center

Phase 1

Kansas City, Kansas1 trial

Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

The University of Kansas Cancer Center, Westwood Campus

Phase 1/2

Chapel Hill, North Carolina1 trial

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.